docetaxel + anthracycline + cyclophosphamide (Xijing Hospital)

Docetaxel + anthracycline + cyclophosphamide is a combination chemotherapy regimen used as neoadjuvant therapy for breast cancer. The regimen typically involves the sequential administration of docetaxel, a taxane that promotes microtubule assembly and inhibits disassembly, followed by a combination of an anthracycline (such as doxorubicin or epirubicin) and cyclophosphamide. Anthracyclines exert their cytotoxic effects through DNA intercalation and inhibition of topoisomerase II, while cyclophosphamide acts as an alkylating agent that forms DNA cross-links. This specific regimen is being studied by Xijing Hospital in a Phase 4 clinical trial (NCT04142099) to evaluate its efficacy and safety in patients with hormone receptor-positive (HR+), HER2-negative primary invasive breast cancer, specifically comparing it against a dose-dense nab-paclitaxel-based regimen.

Other names

T-ACDocetaxel followed by ACDocetaxel + Anthracycline + Cyclophosphamide